Evidence map›Paper›PMID 37869069›Full record

ArticleExploratory research in clinical and social pharmacy2023

The impact of implementing an allergic rhinitis clinical management pathway (AR-CMaP) in the community pharmacy.

Rachel House, Vicky Kritikos, Biljana Cvetkovski, Janet Rimmer, Kwok Yan, Lynn Cheong, Jean Bousquet, Olga Lourenco, Sinthia Bosnic-Anticevich

Abstract read
In one paragraph

Article in Exploratory research in clinical and social pharmacy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Corticosteroids sparing effect of artemisia annua sublingual immunotherapy: A prospective study in pediatric seasonal allergic rhinoconjunctivitis (INCs sparing and efficacy of Artemisia annua SLIT in pediatric SARC).European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rachel HouseQuality Use of Respiratory Medicines Group, Woolcock Institute of Medical Research, Glebe, NSW, Australia.
Vicky KritikosQuality Use of Respiratory Medicines Group, Woolcock Institute of Medical Research, Glebe, NSW, Australia.
Biljana CvetkovskiQuality Use of Respiratory Medicines Group, Woolcock Institute of Medical Research, Glebe, NSW, Australia.
Janet RimmerMacquarie University, Macquarie Park, NSW, Australia.
Kwok YanQuality Use of Respiratory Medicines Group, Woolcock Institute of Medical Research, Glebe, NSW, Australia.
Lynn CheongDiscipline of Pharmacy, University of Canberra, Canberra, Australia.
Jean BousquetMACVIA-France, Contre les Maladies Chroniques pour un Vieillissement Actif en France, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France.
Olga LourencoFaculty of Health Sciences and CICS-UBI, Health Sciences Research Centre, University of Beira Interior, 6200-506 Covilhã, Portugal.
Sinthia Bosnic-AnticevichQuality Use of Respiratory Medicines Group, Woolcock Institute of Medical Research, Glebe, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The Allergic Rhinitis Clinical Management Pathway (AR-CMaP) was developed to overcome the challenge of implementing current AR guidelines in the Australian community pharmacy practice and support pharmacists in optimally managing patients' AR. Objectives: To evaluate the impact of AR-CMaP on patients' behaviour and pharmacists' needs in managing AR in the pharmacy. Methods: This study used a cross-sectional, pre-post study design in which the primary outcome was the appropriateness of medications purchased from community pharmacies in Australia. Patient data were collected before and after the implementation of AR-CMaP. Pharmacist needs were recorded before and after AR-CMaP training. Data were analysed descriptively. Results: Six pharmacies, 19 pharmacists and a total of 416 patients were included in the study; 206 pre-AR-CMaP implementation and 210 post-AR-CMaP implementation. Pre-AR-CMaP, 22.4% of patients purchased appropriate AR medication compared with 29.0% post-AR-CMaP implementation. Over half the patient cohort (52%) consulted a pharmacist pre-AR-CMaP and 37% consulted a pharmacist post-AR-CMaP implementation. Post-AR-CMaP, pharmacists reported increased awareness of barriers such as patients' lack of time, patients' perceptions about the pharmacist's role and patient choice to self-manage. Pharmacists also rated an increased desire to interact with other health care providers (HCPs) in caring for patients with AR. Conclusions: While there was a non-statistically significant increase in the proportion of patients purchasing optimal AR medication, AR-CMaP did empower patients to self-select their own medication without further detriment. Moreover, following the implementation of AR-CMaP, pharmacists developed a greater awareness of their role in AR management, exemplified by their increased desire to be actively involved in AR management and increased interaction with other HCPs. Future research needs to explore more effective tools to support pharmacists' clinical decision-making and target patients' self-selection of AR medications. This study highlights that there is an ingrained self-reliance of AR decision-making that has become a habit for people living with AR.

Indexed as

Allergic rhinitisCommunity pharmacyGuidelinePharmacistSelf-selectSuboptimal management

Identifiers

PMID37869069
PMCPMC10585337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.